RIL
VRDN icon

Rothschild Investment LLC’s Viridian Therapeutics VRDN Stock Holding History

Rothschild Investment LLC’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89K Buy
266
+130
+96% +$2.1K ﹤0.01% 2276
2026
Q1 		$2.66K Sell
136
-1
-0.7% -$30 ﹤0.01% 2408
2025
Q4 		$4.26K Buy
137
+7
+5% +$192 ﹤0.01% 1975
2025
Q3 		$2.81K Sell
130
-40
-24% -$721 ﹤0.01% 2011
2025
Q2 		$2.38K Buy
170
+55
+48% +$746 ﹤0.01% 1956
2025
Q1 		$1.55K Buy
115
+40
+53% +$681 ﹤0.01% 2063
2024
Q4 		$1.44K Buy
75
+5
+7% +$109 ﹤0.01% 2001
2024
Q3 		$1.59K Buy
70
+30
+75% +$490 ﹤0.01% 1849
2024
Q2 		$520 Buy
40
+35
+700% +$485 ﹤0.01% 1987
2024
Q1 		$88 Buy
+5
New +$97 ﹤0.01% 2237

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rothschild Investment LLC's VRDN Position: Q2 2026 in Review

Rothschild Investment LLC increased its Viridian Therapeutics (VRDN) stake by 96% in Q2 2026, buying an estimated $2.1K and bringing the position to 266 shares worth $4.89K. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

Rothschild Investment LLC first reported a position in VRDN in Q1 2024 and has held it in 10 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Rothschild Investment LLC held 266 shares of Viridian Therapeutics worth $4.89K as of Q2 2026.
  • Rothschild Investment LLC bought 130 Viridian Therapeutics shares in Q2 2026, an estimated $2.1K.
  • Viridian Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2276 holding.
  • Rothschild Investment LLC first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.